Caroline Loew, Ph.D. is the chief executive officer of Mural Oncology.
Dr. Loew’s biopharmaceutical career spans more than 25 years of drug development and commercialization experience. She most recently served as president and CEO at Glympse Bio, a biotechnology company based in Cambridge, Mass. Prior to Glympse Bio, Dr. Loew was vice president and head of R&D Strategy and Planning at Bristol-Myers Squibb (BMS). At BMS, she led portfolio strategy and operations in a broad role that included delivering strong competitive positioning for the Immuno-Oncology, Immunoscience, Fibrosis and Cardiovascular portfolios, as well as a fit-for-purpose operating model. Dr. Loew joined BMS following leadership roles at Merck and PhRMA, where she led market access, commercial portfolio management, and regulatory policy.
Dr. Loew earned her Ph.D. in Organic Chemistry and B.Sc. in Chemistry from Imperial College London.